Adamax vs Semax: the main differences between nootropic peptides

Adamax and Semax are synthetic peptides studied in neurobiology and in the context of nootropic substances. Although they are related in terms of structure, they differ significantly in their scientific development history, molecular properties, regulatory status, and the range of available clinical evidence. To understand the differences between Semax and Adamax, it is necessary to examine their origin, chemical structure, proposed mechanisms of action, stability, safety, and limitations of current research.

What are Semax and Adamax?

Semax is a synthetic heptapeptide with the amino acid sequence Met–Glu–His–Phe–Pro–Gly–Pro (MEHFPGP). It was developed in the Soviet Union in the 1980s based on fragments of the adrenocorticotropic hormone (ACTH) [1, 3]. Unlike many experimental neuropeptides, Semax has moved from laboratory research to being approved for medical use in Russia. Scientists have analyzed its properties in animal models and in human studies, particularly with regard to neurological, vascular-brain, ophthalmological, gastrointestinal, immune-related disorders, and stress responses [3–8, 11–13].

Adamax is a synthetic neuropeptide that was later developed as a chemically modified analog of Semax. It is usually described as a compound containing acetylation of the N-terminus and additional structural modifications, including an element associated with adamantan [14–18]. These modifications are associated with attempts to increase the stability of the molecule and its resistance to enzymatic degradation. However, the proposed benefits remain primarily the subject of experimental research. Unlike Semax, Adamax has not yet found a well-established clinical application or been approved for marketing as a medicinal product [15, 21].

Although both peptides belong to a related structural group, their history of research is distinctly different. Semax has been studied for several decades in laboratory experiments, animal studies, and clinical trials involving humans. The direct evidence base for Adamax is significantly smaller, and many claims about its properties are based on structural comparisons or results from studies of related compounds.

This difference is fundamental when comparing Adamax and Semax. Semax has documented clinical experience and a specific regulatory status in Russia, although its approval does not extend to many other countries. Adamax remains an experimental compound without comparable clinical validation.

Structural and molecular differences

The main differences in the structure of Semax and Adamax result from chemical modifications, rather than from a completely different origin of these peptides.

Semax is a linear heptapeptide derived from the ACTH(4–10) fragment. Its structure was designed to preserve selected biological properties of the original ACTH fragment while improving stability [1, 9]. The molecule was studied with regard to neurotrophic signaling and melanocortin-related pathways without introducing large lipophilic structural groups.

Adamax retains a peptide backbone related to Semax, but is described as a compound containing acetylation at the N-terminus and a modification based on adamantane [16, 18]. These additional elements distinguish it from the original Semax molecule.

Adamantan is a rigid, lipophilic chemical structure also studied in compounds with neurological effects, such as amantadine [19, 20]. Introducing this structure into designed molecules can affect physicochemical properties, including lipophilicity and interactions with the biological environment. However, it is not possible to directly transfer the results of studies on amantadine to Adamax, as these compounds have a different molecular structure.

Modifications attributed to Adamax increase the size of its molecule and alter its physicochemical properties. The reported molecular masses are approximately 984–1032 g/mol, depending on the molecular form described [16]. For comparison, the molecular mass of Semax is approximately 750 g/mol.

Structural differences provide the basis for investigating Adamas as a potentially more stable derivative. However, chemical modification, which appears beneficial at the molecular design stage, does not automatically lead to greater biological activity, better brain penetration, clinical efficacy, or safety.

Adamax should therefore be considered primarily as a modified analog of Semax, and not as a representative of a completely separate class of neuropeptides.

Mechanism of action: similarities and differences

The mechanisms discussed in the studies comparing Semax and Adamax are primarily related to neurotrophic signaling, the regulation of neurotransmitters, and the biological consequences of peptide modification. However, the strength of the evidence supporting these mechanisms varies significantly.

Mechanism of action of Semax

Semax has been studied at the molecular and cellular levels, in animal models, and in human studies. Experimental results link it to ACTH- and melanocortin-dependent signaling pathways, as well as to changes in neurotrophic and neurotransmitter systems.

One important area of research is neurotrophic brain-derived factor (BDNF) and its receptor TrkB. In studies in rats, changes in BDNF and TrkB expression were observed in areas of the brain such as the hippocampus and the primary forebrain [9, 10]. These results are important because BDNF is involved in neuron development, synaptic plasticity, and cellular responses to neurological stress.

Semax has also been studied for its effects on dopaminergic and serotoninergic signaling. In experiments, changes in dopamine release and serotonin-related processes were observed. This suggests that the peptide may act on several neurotransmitter pathways, rather than acting through a single isolated mechanism [1].

Additional studies included changes in the expression of genes related to immune response, blood vessel regulation, inflammation, and cellular responses to ischemic injury [4–7]. These observations suggest that Semax-related signaling may involve interactions between neuronal and immune processes.

Clinical studies also analyzed Semax in patients after ischemic stroke and with other neurological diseases. In some studies, improvements in neurological or functional outcomes were reported, while in experiments changes in neurotrophic factors and molecular markers associated with ischemic damage were observed [3–7].

However, it is necessary to distinguish between individual results. Changes in BDNF expression, neurotransmitter activity, or the expression of genes related to immunity do not constitute independent evidence of clinical benefit. Similarly, the results obtained in animal models cannot be automatically equated with observations in patients.

Available evidence indicates several experimentally investigated pathways of action of Semax. However, the precise role of each of these mechanisms in the observed clinical outcomes remains a separate scientific issue.

Mechanism of action of Adamax

The proposed mechanism of action of Adamax is much less well understood. Much of the discussion is based on its structural similarity to Semax and broader studies of modified neurotrophic peptides.

Adamax is often discussed in the context of BDNF signaling, TrkB receptor-related pathways, and possible effects on neurotransmitter systems involving dopamine, glutamate, gamma-aminobutyric acid (GABA), and acetylcholine.

However, the proposed relationships should be considered hypotheses rather than mechanisms confirmed in humans. There is no established evidence from direct, controlled clinical trials that demonstrate such an effect of Adamax.

Its chemical modifications have also led to the assumption that Adamax may influence the duration of action or the effectiveness of neuropeptide signaling. The rationale for this hypothesis assumes that changes in the stability of the molecule and its lipophilicity may affect the behavior of the compound in the biological environment.

It remains a structural and theoretical interpretation. It does not prove that Adamax produces longer-lasting neurological effects, stronger receptor signaling, or better cognitive outcomes.

Distinction is therefore important: in the case of Semax, there are experimental studies of molecular pathways, as well as clinical studies involving humans, whereas the proposed mechanisms of Adamax are based to a much greater extent on indirect evidence and chemical considerations.

Comparison of the mechanisms of action

Both peptides are discussed in studies of neurotrophic and neurochemical processes, but their proposed activity should not be considered equivalent.

In the case of Semax, the studies directly analyzed changes in signaling related to BDNF, neurotransmitter systems, gene expression, and selected neurological outcomes.

Similar effects of Adamax are often proposed due to its similarity to Semax and the nature of the chemical modifications. However, the presence of a similar peptide sequence does not prove that both compounds act on biological targets in the same way.

Chemical modification can alter the stability of the molecule, its distribution, interactions with receptors, metabolism, and other properties. These changes can lead to different biological behavior, and not merely to an enhancement of the activity of the original peptide.

As a result, Semax has a more developed evidence base of experimental and clinical studies regarding its mechanisms of action, while Adamax remains largely in the stage of mechanistic research and hypothesis formulation.

Semax vs Adamax: comparative table

The table primarily shows the difference in the level of research advancement, and does not prove that one compound is always more effective than the other. Semax has a much larger database of direct studies, while Adamax remains less well characterized.

Time of operation, stability and context of the research

Stability is one of the most frequently discussed differences between Adamax and Semax.

Like many biologically active peptides, Semax can undergo enzymatic degradation. Studies have analyzed its stability in the biological environment and the ways it maintains its activity through molecule design and appropriate formulation solutions [2, 9].

The investigational products also formed part of the clinical development of Semax. However, the properties of the formulations and the route of administration should not be confused with the evidence that the peptide remains active for a specified period of time in each tissue.

Adamax was developed based on the assumption that additional chemical modifications can alter the stability of the peptide. Acetylation of the N-terminus and structural elements associated with adamantan are discussed as possible factors that enhance resistance to proteolytic degradation and the duration of the compound in experimental systems [16, 17].

These properties are of scientific importance because the enzymatic degradation can affect the time during which a peptide remains intact in the biological environment.

However, chemical stability and clinical duration of action are two different concepts. A molecule that is resistant to degradation under laboratory conditions does not necessarily cause persistent effects in the human nervous system.

The time of action under clinical conditions also depends on absorption, distribution, metabolism, elimination, interaction with the biological target, and the relationship between the exposure to the molecule and the biological response.

In the case of Adamax, standardized pharmacokinetic measurements in humans are not available, nor are established data on the elimination half-life. Furthermore, no established direct studies comparing its duration of action with Semax in humans have been conducted.

Therefore, claims that Adamax lasts longer than Semax should be understood as proposed molecular-based consequences, and not confirmed clinical results.

A broader discussion of the factors influencing the stability of molecules can be found in the article Storage of peptides: temperature, humidity and the effect of freezing. It is worth noting that the stability during storage is different from the time the compound remains in the body.

Safety, tolerance and limitations of research

The available information on the safety of Semax and Adamax differs primarily because these compounds are in different stages of research.

Safety and tolerance of Semax

Semax has been studied in Russia in various patient populations, including for cerebrovascular and neurological disorders. Published clinical trials provide information on its tolerability under the tested conditions.

Among the reported adverse reactions, headache, irritation of the nasal mucosa, nausea, anxiety, and sleep-related disturbances were most frequently mentioned. In the available literature, these symptoms were often described as mild or transient.

The clinical studies also included older people and patients receiving repeated cycles of treatment due to cerebrovascular diseases. These studies add additional information to the available evidence base on safety in humans.

However, favorable results regarding tolerability should not be interpreted as proof of complete safety. The credibility of such a conclusion depends on the study design, the characteristics of the participants, the size of the sample, the duration of observation, the method of monitoring adverse effects, and the ability to detect rare or delayed consequences.

Semax is also not approved for sale as a drug in many countries outside of Russia. Differences in regulatory recognition should not be automatically attributed to a single cause, such as confirmed toxicity or a lack of safety concerns. Regulatory decisions depend on the evidence and requirements in place in a given country.

Semax therefore has a much broader database of safety data in humans than Adamax, but this does not prove its universal safety in all populations, formulations, and circumstances.

Safety and tolerance at Adamax

Adamax does not have a comparable database of controlled human safety studies.

Most available studies concern the chemical structure, proposed biological mechanisms, theoretical properties, and relationships that do not provide the reliability of the methodological approaches appropriate for controlled clinical trials.

Anecdotal observations do not allow for determining the frequency, severity, or causes of adverse events. They also do not allow for reliable detection of rare events or assessment of long-term safety.

Although Adamax is structurally related to Semax, the safety testing results of Semax cannot simply be transferred to its modified analog.

Changes in molecular structure can affect absorption, distribution, metabolism, interactions with tissues, and other biological properties. Therefore, structural similarity alone is not sufficient to establish equivalent tolerance.

The lack of extensive safety data for Adamas in humans should not be interpreted as evidence of its toxicity. It also cannot be considered as confirmation of the safety of the compound.

The safety profile of Adamas remains insufficiently known and constitutes one of the most important limitations of the available studies.

Comparison of evidence regarding safety

Semax has documented clinical trials involving humans that allow researchers to analyze reported adverse effects and tolerability under specific treatment conditions.

In the case of Adamax, there are no comparable controlled studies involving humans.

The difference therefore mainly concerns the availability of evidence and the degree of scientific certainty.

The tolerance described for Semax is confirmed by clinical observations, although these evidence still has limitations. The safety of Adamax remains uncertain due to insufficient direct data derived from human studies.

None of these conclusions proves that the compounds are interchangeable or that the results regarding one of them allow for reliably predicting the safety of the other.

Semax vs Adamax: the most important differences

The most important differences between these compounds can be considered in three related areas: molecular structure, the degree of advancement of research, and clinical recognition.

Semax is a reference compound with a well-established amino acid sequence, a decades-long history of experimental research and clinical trials in Russia. Its molecular and biological properties have been analyzed with regard to neurotrophic signaling, neurotransmitter systems, and several neurological disorders.

Adamax is a modified analog whose structure includes additional chemical elements. These modifications form the basis for studying stability and biological interactions, but in themselves they do not prove better efficacy or clinical effectiveness.

The biggest difference concerns the gap in available evidence. Semax has been directly studied in humans and has a specific regulatory status in one national health care system. Adamax remains an experimental research compound, without comparable controlled human studies and approved therapeutic indications.

Which peptide is better studied?

Semax is definitely more well-researched than Adamax.

The history of his research includes several decades of laboratory experiments, animal studies, and clinical trials involving humans. Scientists analyzed its molecular mechanisms, neurological effects, and possible applications in conditions related to vascular and brain damage, neuroprotection, disorders of the optic nerve, gastrointestinal processes, immune regulation, stress responses, and cognitive functions.

Semax has also been approved for certain medical uses in Russia. This regulatory history distinguishes it from many experimental neuropeptides, although approval in one country does not mean approval in other countries.

The available literature includes controlled and observational studies, as well as molecular studies analyzing pathways related to BDNF, neurotransmitter activity, and gene expression associated with the immune system [1–13].

Adamax has a much narrower evidence base. There is a lack of well-established controlled clinical trials involving humans, approved therapeutic indications, and reliable data on long-term safety and clinical outcomes [21].

Its proposed properties are discussed primarily based on chemical modifications, structural similarities, and broader studies of neurotrophic peptides.

This difference does not prove that Semax is effective in all proposed applications. It also does not mean that Adamax cannot exhibit biological activity.

It does, however, show that both compounds are at different stages of scientific evaluation.

Semax has a larger base of directly relevant evidence, while many questions regarding Adamax remain unanswered.

More information about the importance of regulatory approval and the differences between the compound under study and the approved medicinal product are presented in the article. Approved peptide drugs.

Summary

Semax and Adamax are structurally related synthetic neuropeptides, however their scientific development and available evidence differ significantly.

Semax is a heptapeptide derived from ACTH that has gone from laboratory research to clinical trials and approval for medical use in Russia. Its biological properties have been analyzed in studies involving neurotrophic signaling, neurotransmitter regulation, ischemic damage, and the expression of genes related to immunity, as well as selected neurological diseases.

Adamax is a later experimental modification of the molecular backbone related to Semax. Its structural changes, including acetylation of the N-terminus and an element associated with adamantan, form the basis for studying the stability of the molecule, resistance to degradation, and possible changes in biological interactions.

However, the proposed properties have not been confirmed to have better clinical effects. Adamax lacks comparable controlled human studies with Semax, standardized pharmacokinetic data, long-term safety results, or regulatory approval.

Distinguishing is particularly important when comparing mechanisms of action. In the case of Semax, the molecular pathways and clinical results in humans have been directly studied, whereas many of the proposed mechanisms for Adamax still rely on indirect evidence and structural considerations.

Their safety profiles cannot also be considered equivalent. Semax has documented tolerance data in humans under specific study conditions, whereas Adamax remains insufficiently characterized in the human population.

Ultimately, the most important difference between Semax and Adamax is not the proven superiority in terms of potency, duration of effects, or improvement in cognitive functions. It is the degree of scientific certainty with which each of these compounds can be evaluated.

Semax has a much more developed database of experimental and clinical evidence. Adamax remains the subject of research in experimental neuroscience and peptide chemistry, and important questions regarding its biological activity, pharmacokinetics, clinical results, and safety remain unanswered.

Disclaimer

This article is for educational and scientific informational purposes only. It compares the molecular structure, the results of the studies, the proposed mechanisms of action, the regulatory status, and the evidence regarding the safety of Semax and Adamax.

It does not constitute medical advice, does not recommend the use of any of these compounds, does not confirm clinical efficacy in unapproved indications, and does not contain instructions regarding dosage, administration, or individual use.

The approval of Semax in Russia does not mean its approval in other countries. Adamax remains an experimental compound without established clinical confirmation and sufficient safety data from controlled human studies.

The results of animal experiments, molecular studies, structural comparisons, and theoretical mechanisms should not be interpreted as evidence of clinical benefits or safety in humans.  

References

1. Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., Rayevsky, K. S. Semax, an ACTH(4–10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 2005; 30(12): 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
2. Shevchenko, K. V., Nagaev, I. Y., Andreeva, L. A., Shevchenko, V. P., Myasoedov, N. F.
   Stability of Semax acetyl to proteolysis in various biological media. Biological Sciences, 2013; 449(1): 110–112.
3. Gusev, E. I., Martynov, M. Y., Kostenko, E. V., Petrova, L. V., Bobyreva, S. N. The efficacy of Semax in the treatment of patients at different stages of ischemic stroke. Journal of Neurology and Psychiatry named S.S. Korsakov, 2018; 118(3): 61–68. https://doi.org/10.17116/jnevro20181183261-68
4. Medvedeva, E. V., Dmitrieva, V. G., Limborska, S. A., Myasoedov, N. F., Dergunova, L. V. Semax regulates the expression of immune response genes during ischemic brain injury in rats. Molecular Genetics and Genomics, 2017; 292(3): 635–653. https://doi.org/10.1007/s00438-017-1297-1
5. Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., et al. The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia. BMC Genomics, 2014; 15: 228. https://doi.org/10.1186/1471-2164-15-228
6. Dergunova, L. V., Dmitrieva, V. G., Filippenkov, I. B., et al. Molecular mechanisms of Semax neuroprotection in cerebral ischemia. Molecular Biology, 2021; 55(3): 402–411.
7. Sudarkina, O. Y., Filippenkov, I. B., Stavchansky, V. V., et al. The brain protein expression profile confirms the protective effect of Semax in cerebral ischemia-reperfusion. International Journal of Molecular Sciences, 2021; 22(12): 6179. https://doi.org/10.3390/ijms22126179
8. Serdiuk, A. V., Levitskii, G. N., Myasoedov, N. F., Skvortsova, V. I. Clinical use of Semax in motor neuron disease. Journal of Neurology and Psychiatry, 2007; 107(4): 29–39.
9. Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., et al. Semax regulates BDNF and TrkB expression in the rat hippocampus. Brain Research, 2006; 1117(1): 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
10. Dolotov, O. V., Karpenko, E. A., Seredenina, T. S., et al. Semax binds specifically and increases BDNF protein levels in rat basal forebrain. Journal of Neurochemistry, 2006; 97(Suppl 1): 82–86. https://doi.org/10.1111/j.1471-4159.2006.03658.x
11. Ivanikov, I. O., Brekhova, M. E., Samonina, G. E., Myasoedov, N. F., Ashmarin, I. P. Therapy of peptic ulcer with Semax peptide. Bulletin of Experimental Biology and Medicine, 2002; 134(1): 73–74.
12. Gusev, E. I., Skvortsova, V. I., Chukanova, E. I. Semax in cerebrovascular insufficiency.
    Journal of Neurology and Psychiatry, 2005; 105(2): 35–40.
13. Polunin, G. S., Nurieva, S. M., Baiandin, D. L., Andreeva, L. A. Evaluation of Semax in optic nerve disease. Vestnik Oftalmologii, 2000; 116(1): 15–18.
14. Ponomareva-Stepnaya, M. A., Achfeeva, L. Y., Maksimova, L. A. Synthesis and investigation of ACTH fragments and analogs – memory stimulators. Pharmaceutical Chemistry Journal, 1981; 15(10): 720–725.
15. Government of the Russian Federation. Directive No. 2738-r, dated 10 December 2018.
    Moscow, Russian Federation.
16. Magrì, A., Tabbì, G., Giuffrida, A., et al. Influence of N-terminal acetylation of Semax on biological properties. Journal of Inorganic Biochemistry, 2016; 164: 59–69. https://doi.org/10.1016/j.jinorgbio.2016.08.013
17. Chohan, M. O., Li, B., Blanchard, J., et al. Enhancement of neurogenesis and synaptic plasticity by neurotrophic peptides. Neurobiology of Aging, 2011; 32(8): 1420–1434.
18. Li, B., Wanka, L., Blanchard, J., et al. Neurotrophic peptides including adamantane improve learning and memory in mice. FEBS Letters, 2010; 584(15): 3359–3365. https://doi.org/10.1016/j.febslet.2010.06.025
19. Giacino, J. T., Whyte, J., Bagiella, E., et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. New England Journal of Medicine, 2012; 366(9): 819–826. https://doi.org/10.1056/NEJMoa1102609
20. Morrow, K., Choi, S., Young, K., et al. Amantadine for the treatment of childhood and adolescent psychiatric symptoms. Proceedings of the Baylor University Medical Center, 2021; 34(5): 566–570.
21. Baazaoui, N., Iqbal, K. A neurotrophic support approach to Alzheimer’s disease. Journal of Alzheimer’s Disease, 2018; 62(3): 1211–1218.